
Get access to Hummingbird’s miRNA Biomarker Platform
Partnering
Enhanced clinical drug development
- Patient stratification (responders)
- Disease & treatment monitoring marker
- Immunological status
- Toxicological & adverse event marker
Diagnostic development
- Early diagnosis
- Prognosis
- Companion Diagnostics
Access to ip portfolio
- Out-licensing
- Co-development
Interested in collaboration?
Please contact us!
Get access to Hummingbird’s miRNA Biomarker Platform
IP
Dominant IP in whole blood
- 34 patent families
- Encompassing all major disease groups
- 140 patents granted/validated
Access to ip portfolio
- Out-licensing
- Co-development